Glucagon-like peptide-1 receptor agonist variants and methods thereof
OwnerYen Huei LIN, Jaehee SHIN +3inventors
InventorsYen Huei LIN, Jaehee SHIN, Subramanya KARANTH, Adam BELL, Viktor ROSCHKE
Life of this patent
Estimating the term…
Loading patent…
OwnerYen Huei LIN, Jaehee SHIN +3inventors
InventorsYen Huei LIN, Jaehee SHIN, Subramanya KARANTH, Adam BELL, Viktor ROSCHKE
Estimating the term…
Glucagon-like peptide-1 (GLP-1) receptor agonists and analogs thereof having one or more amino acids substituted to reduce immunogenicity and antigenicity are described. These GLP-1R agonists and analogs have comparable or better physicochemical properties and pharmacokinetics in a mammalian host relative to GLP-1 RAs currently available for treatment. Compositions and formulations of these agonist peptides are particularly suited for treating, alleviating, and/or preventing one or more metabolic diseases such as obesity, diabetes mellitus, and non-alcoholic fatty liver disease, as well as one or more neurodegenerative disease such as Alzheimer's disease (AD) and Parkinson's disease (PD).
A Glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide or analog thereof having activities towards a GLP-1 receptor, comprising the amino acid sequence of
The GLP-IRA peptide or analog of 12, wherein the multiple-branched polyethylene glycol is a 3-arm branched PEGs having a molecular weight of between 20 kDa and 250 kDa.
28-29. (canceled)
(canceled)
Dependencies are inferred from the claim text.